Lead Product(s) : MK-3000
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck and EyeBio Initiate Phase 2b/3 Trial for Restoret™ in Diabetic Macular Edema
Details : Restoret (MK-3000), a first-in-class tetravalent, tri-specific antibody and late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration.
Brand Name : Restoret
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 04, 2024
Lead Product(s) : MK-3000
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Azura Enrolls First Patient in Phase 3 Trial for MGD Treatment AZR-MD-001
Details : AZR-MD-001 is an ophthalmic ointment, applied directly to the meibomian glands. It is under clinical development for the patients with Contact Lens Discomfort & Meibomian Gland Dysfunction.
Brand Name : AZR-MD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 04, 2024
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AVD-104
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aviceda Doses First Patient in Phase 2/3 SIGLEC Trial for Geographic Atrophy
Details : AVD-104 is a novel small molecule inhibiting neutrophil/macrophage activation, currently in phase 2/3 trials for treating geographic atrophy from macular degeneration.
Brand Name : AVD-104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 01, 2024
Lead Product(s) : AVD-104
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AVD-104
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aviceda Reports Positive Phase 2/3 Data for AVD-104 in Geographic Atrophy
Details : AVD-104 is a novel complement pathway modulator under evaluation in phase 2/3 trials for geographic atrophy secondary to macular degeneration.
Brand Name : AVD-104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2024
Lead Product(s) : AVD-104
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AZR-MD-001 is an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands in the lower eyelid. It is under phase 3 clinical development for the patients with Contact Lens Discomfort (CLD) & Meibomian Gland Dysfunction (MGD).
Brand Name : AZR-MD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 18, 2023
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCS-01 is developed using the Optireach® solubilizing technology, a proprietary platform that enables the formulation of drugs as topical eye drop treatment with cystoid macular edema.
Brand Name : OCS-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction.
Brand Name : AZR-MD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2022
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ALY688
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALY688 Ophthalmic Solution contains ALY688, a novel first-in-class peptide with broad anti-inflammatory and corneal epithelial regenerative properties. ALY688 Ophthalmic Solution was well tolerated with a low rate of post-instillation reactions.
Brand Name : ALY688
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 08, 2022
Lead Product(s) : ALY688
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : European Biotech Acquisition Corp
Deal Size : $80.0 million
Deal Type : Merger
Details : The proceeds expected to support advanced clinical pipeline of multiple innovative products, potentially including the first topical eye-drop for OCS-01 (dexamethasone), the first biologic eye-drop for DED and the first neuroprotective agent for neuro-re...
Brand Name : OCS-01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : European Biotech Acquisition Corp
Deal Size : $80.0 million
Deal Type : Merger
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : CUREator
Deal Size : Undisclosed
Deal Type : Funding
Details : The grant will support Azura’s two-stage study evaluating the safety, tolerability and efficacy of the company’s lead clinical candidate, AZR-MD-001, in patients with contact lens discomfort (CLD) who show evidence of Meibomian gland dysfunction (MGD...
Brand Name : AZR-MD-001
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 07, 2022
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : CUREator
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?